Hodgkin lymphoma (HL) is one of the most common non-AIDS-defining malignancies in patients infected with HIV. Unfavorable features such as higher frequency of advanced-stage disease and extranodal involvement are frequently encountered. Prior to the advent of combined antiretroviral therapy (cART), the prognosis of patients with HIV-HL was poor. However, with standard curative-intent therapy and modern cART, the outcome is similar to that reported in the general population. In patients with early favorable HL two cycles of ABVD followed by involved-field radiation (IF-RT) is considered standard of care. Patients with early unfavorable HL should receive four cycles of ABVD + IF-RT while six cycles of ABVD or six cycles of BEACOPP baseline should be given to patients with advanced HIV-HL.
CITATION STYLE
Hentrich, M., Spina, M., & Montoto, S. (2016). HIV-associated Hodgkin lymphoma. In HIV-Associated Hematological Malignancies (pp. 119–132). Springer International Publishing. https://doi.org/10.1007/978-3-319-26857-6_9
Mendeley helps you to discover research relevant for your work.